Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.

Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.

Item
http://www.wikidata.org/entity/Q44146085
Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures.Ciprofloxacin dosage and emergence of resistance in human commensal bacteriaDuration of outpatient fecal colonization due to Escherichia coli Isolates with decreased susceptibility to fluoroquinolones: longitudinal study of patients recently discharged from the hospitalFluoroquinolone-resistant Escherichia coli carriage in long-term care facilityPrevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy.Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis.Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: A single-centre study.Natural history of colonization with gram-negative multidrug-resistant organisms among hospitalized patients.Effect of Lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora.Relapsing bloodstream infections during treatment of acute leukemia.
P2860

Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.

Item
http://www.wikidata.org/entity/Q44146085
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Incidence and clinical impact ...... and ciprofloxacin prophylaxis.
@en
Incidence and clinical impact ...... and ciprofloxacin prophylaxis.
@nl
type
label
Incidence and clinical impact ...... and ciprofloxacin prophylaxis.
@en
Incidence and clinical impact ...... and ciprofloxacin prophylaxis.
@nl
prefLabel
Incidence and clinical impact ...... and ciprofloxacin prophylaxis.
@en
Incidence and clinical impact ...... and ciprofloxacin prophylaxis.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Incidence and clinical impact ...... and ciprofloxacin prophylaxis.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921